192 related articles for article (PubMed ID: 28025783)
21. Idelalisib immune-related toxicity is associated with improved treatment response.
Wagner-Johnston ND; Sharman J; Furman RR; Salles G; Brown JR; Robak T; Gu L; Xing G; Chan RJ; Rajakumaraswamy N; Gopal AK
Leuk Lymphoma; 2021 Dec; 62(12):2915-2920. PubMed ID: 34319205
[TBL] [Abstract][Full Text] [Related]
22. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
23. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
Lopez JP; Jimeno A
Drugs Today (Barc); 2014 Feb; 50(2):113-20. PubMed ID: 24619588
[TBL] [Abstract][Full Text] [Related]
24. Idelalisib approved for three blood cancers.
Traynor K
Am J Health Syst Pharm; 2014 Sep; 71(17):1430. PubMed ID: 25147161
[No Abstract] [Full Text] [Related]
25. Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia.
Lafon-Desmurs B; Monsel G; Leblond V; Papo M; Caumes E; Fekkar A; Jaureguiberry S
Med Mal Infect; 2017 Jun; 47(4):293-296. PubMed ID: 27818019
[No Abstract] [Full Text] [Related]
26. Idelalisib for chronic lymphocytic leukemia.
Brown JR
Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
[No Abstract] [Full Text] [Related]
27. [Polymicrobial lung infection associated with idelalisib administration].
Rodríguez-Ferreras A; Velasco-Roces L; Lázaro-López E; Zapico-García I
Farm Hosp; 2018 Jan; 42(1):25-26. PubMed ID: 29306311
[No Abstract] [Full Text] [Related]
28. Idelalisib for the treatment of non-Hodgkin lymphoma.
Graf SA; Gopal AK
Expert Opin Pharmacother; 2016; 17(2):265-74. PubMed ID: 26818003
[TBL] [Abstract][Full Text] [Related]
29. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
Hanlon A; Brander DM
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):346-356. PubMed ID: 33275709
[TBL] [Abstract][Full Text] [Related]
30. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
Hewett YG; Uprety D; Shah BK
J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
[TBL] [Abstract][Full Text] [Related]
31. Histologic features in colon biopsies can discriminate mycophenolate from GVHD-induced colitis.
Star KV; Ho VT; Wang HH; Odze RD
Am J Surg Pathol; 2013 Sep; 37(9):1319-28. PubMed ID: 24076772
[TBL] [Abstract][Full Text] [Related]
32. Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease.
Marra DE; McKee PH; Nghiem P
J Am Acad Dermatol; 2004 Oct; 51(4):543-6. PubMed ID: 15389188
[TBL] [Abstract][Full Text] [Related]
33. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Davies A
Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
[TBL] [Abstract][Full Text] [Related]
34. Idelalisib-induced pneumonitis.
Gupta A; Li HC
BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27485880
[No Abstract] [Full Text] [Related]
35. Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report.
Marangon M; Pellegrini C; Argnani L; Zinzani PL
Tumori; 2017 Nov; 103(Suppl. 1):e41-e43. PubMed ID: 28967090
[TBL] [Abstract][Full Text] [Related]
36. CD123 is a useful immunohistochemical marker to facilitate diagnosis of acute graft-versus-host disease in colon.
Lin J; Chen S; Zhao Z; Cummings OW; Fan R
Hum Pathol; 2013 Oct; 44(10):2075-80. PubMed ID: 23791208
[TBL] [Abstract][Full Text] [Related]
37. PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
Greenwell IB; Ip A; Cohen JB
Oncology (Williston Park); 2017 Nov; 31(11):821-8. PubMed ID: 29179250
[TBL] [Abstract][Full Text] [Related]
38. Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
Isidori A; Loscocco F; Visani G; Paolasini S; Scalzulli P; Musto P; Perrone T; Guarini A; Pastore D; Mazza P; Tonialini L; Pavone V; De Santis G; Tarantini G
Br J Haematol; 2022 Nov; 199(3):339-343. PubMed ID: 36002151
[TBL] [Abstract][Full Text] [Related]
39. Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity.
Castillo JJ; Gustine JN; Meid K; Dubeau T; Yang G; Xu L; Hunter ZR; Treon SP
Leuk Lymphoma; 2017 Apr; 58(4):1002-1004. PubMed ID: 27562445
[No Abstract] [Full Text] [Related]
40. No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
Barrientos JC; Hillmen P; Salles G; Sharman J; Stilgenbauer S; Gurtovaya O; Xing G; Ruzicka B; Bhargava P; Ghia P; Pagel JM
Leuk Lymphoma; 2021 Apr; 62(4):837-845. PubMed ID: 33297794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
